MEGGLE brings expert insights to RDD respiratory conference
Press Release | MEGGLE Excipients & Technology
APRIL 18, 2018
Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients & Technology (MEGGLE) is returning as a sponsor and exhibitor to the influential Respiratory Drug Delivery Conference, this year in Tucson, Arizona.
MEGGLE will bring to the event a selected range of inhalation quality lactose grades as well as expert knowledge.
Sponsor and Exhibitor
MEGGLE is attending regularly the RDD conference since 2013. For RDD Arizona, it will be both a Silver Sponsor and Exhibitor. At the technical exhibition MEGGLE will showcase their distinguished portfolio, in particular products suitable for dry powder inhalation at table 3.
MEGGLEs scientifically present with a Poster with the title “Influence of storage conditions on micronized lactose and the resulting ternary dry powder inhaler formulations” that examines the effect of water adsorption on the material’s chemical and physical surface properties.
The study was the result of collaboration between MEGGLE, the Department of Pharmaceutics and Biopharmaceutics at Germany’s Kiel University and researchers from Istanbul-based Deva Holding AS.
It demonstrates that careful management of relative humidity (rH) during storage can either positively or negatively influence the active properties of micronized lactose and the resulting interactive mixtures using different devices.
Along with Dr. Kobler, MEGGLE will be represented by two colleagues from MEGGLE USA; Director Ken Seufert and Business Development Director Rishi Pimentel.
“RDD Arizona 2018 will provide us with an ideal platform from which to present our product portfolio, meet leading customers and expert peers and explore latest trends in the respiratory and nasal delivery fields,” commented Dr. Kobler.
About MEGGLE Wasserburg
Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose based excipients and powder technology.
From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.
MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.
A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage form applications, where they can deliver maximum performance.
The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.
About RDD 2018
The Respiratory Drug Delivery Conference (RDD) is acknowledged as one of the leading events in the pulmonary, respiratory and nasal delivery fields, helping to shape regulatory and scientific policies worldwide.
RDD 2018 is a five-day event opening April 22 at the JW Marriott Starr Pass Resort and Spa in Tucson, Arizona.
Apart from a full conference program with up to ten scientific tracks, the conference also features a Scientific Poster Session held in conjunction with the Technology Exhibition over two days.
The event is organized by RDD Online, with more information at: https://www.rddonline.com/rdd/rdd.php?id=15&sid=1.
Margit Bonnetsmüller, Project Manager Marketing, MEGGLE Excipients & Technology Business Group
Tel: +49 8071 73 476